Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series

Journal of the American Academy of Dermatology

Volumn 51, Issue 4, 2004, Pages 570-573

  Singh, Fiza ^a   Lebwohl, Mark G ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; INTERFERON; PSORALEN; STEROID;

ADULT; AGED; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFICACY; ELECTRON BEAM; FEMALE; HUMAN; IRRADIATION; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; PRIORITY JOURNAL; PRURITUS; PUVA; RETROSPECTIVE STUDY; REVIEW; SKIN CARCINOMA; T CELL LYMPHOMA;

EID: 4644340662     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.05.010     Document Type: Article

References (25)

1. F.M. Foss Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies Semin Oncol 27 2000 58 63
2. Y.H. Kim, R.A. Jensen, G.L. Watanabe, A. Varghese, and R.T. Hoppe Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis Arch Dermatol 132 1996 1309 1313
3. H.S. Zackheim, M. Kashani-Sabet, and S. Amin Topical corticosteroids for mycosis fungoides. Experience in 79 patients Arch Dermatol 134 1998 949 954
4. K. Thomsen, H. Hammar, L. Molin, and G. Volden Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group Acta Derm Venereol 69 1989 536 538
5. L. Molin, K. Thomsen, G. Volden, A. Aronsson, H. Hammar, and L. Hellbe Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group Acta Derm Venereol 67 1987 232 236
6. L. Molin, K. Thomsen, G. Volden, P. Jensen, E. Knudsen, and A. Nyfors Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group Acta Derm Venereol 67 1987 179 182
7. M.A. Fung, M.J. Murphy, D.M. Hoss, and J.M. Grant-Kels Practical evaluation and management of cutaneous lymphoma J Am Acad Dermatol 46 2002 325 357
8. M. Duvic, A.G. Martin, Y. Kim, E. Olsen, G.S. Wood, and C.A. Crowley Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent earlystage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593
9. K. Kaltoft, B.H. Hansen, and K. Thestrup-Pedersen Cytogenetic findings in cell lines from cutaneous T-cell lymphoma Dermatol Clin 12 1994 295 304
10. K. Kaltoft, B.H. Hansen, C.B. Pedersen, S. Pedersen, and K. Thestrup-Pedersen Common clonal chromosome aberrations in cytokine-dependent continuous human T-lymphocyte cell lines Cancer Genet Cytogenet 85 1995 68 71
11. K. Kaltoft, C.B. Pedersen, B.H. Hansen, and K. Thestrup-Pedersen Appearance of isochromosome 18q can be associated with in vitro immortalization of human T lymphocytes Cancer Genet Cytogenet 81 1995 13 16
12. L. Karenko, E. Hyytinen, S. Sarna, and A. Ranki Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods J Invest Dermatol 108 1997 22 29
13. L. Karenko, M. Kahkonen, E.R. Hyytinen, M. Lindlof, and A. Ranki Notable losses at specific regions of chromosomes 10q and 13q in the Sezary syndrome detected by comparative genomic hybridization J Invest Dermatol 112 1999 392 395
14. J. Limon, B. Nedoszytko, I. Brozek, A. Hellmann, S. Zajaczek, and J. Lubinski Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sezary syndrome Cancer Genet Cytogenet 83 1995 75 81
15. C.L. Berger, N. Wang, I. Christensen, J. Longley, P. Heald, and R.L. Edelson The immune response to class I-associated tumor-specific cutaneous T- cell lymphoma antigens J Invest Dermatol 107 1996 392 397
16. + tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T- lymphocyte phenotype J Cutan Pathol 21 1994 151 156
17. B.A. Pancake, D. Zucker-Franklin, and E.E. Coutavas The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients J Clin Invest 95 1995 547 554
18. S.I. Lamberg, S.B. Green, D.P. Byar, J.B. Block, W.E. Clendenning, and M.C. Douglas Clinical staging for cutaneous T-cell lymphoma Ann Intern Med 100 1984 187 192
19. P. Chambon A decade of molecular biology of retinoic acid receptors Faseb J 10 1996 940 954
20. K.H. Kraemer, S. Seetharam, M.M. Seidman, A. Bredberg, D. Brash, and H.L. Waters Defective DNA repair in humans: clinical and molecular studies of xeroderma pigmentosum Basic Life Sci 53 1990 95 104
21. K.H. Kraemer, J.J. DiGiovanna, and G.L. Peck Chemoprevention of skin cancer in xeroderma pigmentosum J Dermatol 19 1992 715 718
22. R. Talpur, S. Ward, N. Apisarnthanarax, J. Breuer-Mcham, and M. Duvic Optimizing bexarotene therapy for cutaneous T-cell lymphoma J Am Acad Dermatol 47 2002 672 684
23. S.I. Sherman, J. Gopal, B.R. Haugen, A.C. Chiu, K. Whaley, and P. Nowlakha Central hypothyroidism associated with retinoid X receptor-selective ligands N Engl J Med 340 1999 1075 1079
24. M. Duvic, K. Hymes, P. Heald, D. Breneman, A.G. Martin, and P. Myskowski Bexarotene is effective and safe for treatment of refractory advanced- stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471
25. C. Zhang, P. Hazarika, X. Ni, D.A. Weidner, and M. Duvic Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action Clin Cancer Res 8 2002 1234 1240